Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) shares shot up 7.1% on Monday . The stock traded as high as $12.19 and last traded at $12.09. Approximately 9,303 shares changed hands during trading, a decline of 86% from the average session volume of 68,617 shares. The stock had previously closed at $11.29.
Gyre Therapeutics Trading Up 4.0 %
The stock’s 50-day moving average is $13.67 and its two-hundred day moving average is $12.86.
Hedge Funds Weigh In On Gyre Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of GYRE. Charles Schwab Investment Management Inc. lifted its holdings in Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after acquiring an additional 90,557 shares during the period. Geode Capital Management LLC increased its position in shares of Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares during the last quarter. Advantage Alpha Capital Partners LP bought a new position in shares of Gyre Therapeutics in the 3rd quarter worth approximately $334,000. WINTON GROUP Ltd purchased a new position in shares of Gyre Therapeutics in the second quarter worth approximately $220,000. Finally, Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics during the second quarter valued at approximately $218,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.
About Gyre Therapeutics
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
- Five stocks we like better than Gyre Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What Does a Stock Split Mean?
- 2 Generic Drug Stocks Ready to Surge in 2025
- What Are Dividend Achievers? An Introduction
- 3 Small-Cap Stocks That Are Ready to Rocket Higher
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
